治疗前外周血T细胞受体克隆性高可预测免疫性血小板减少症持久应答
该研究基于XPAG-免疫性血小板减少症试验,比较地塞米松(DEX)与艾曲泊帕(ETB)联合DEX方案,并分析T细胞免疫应答与疗效的关系。结果显示,持续应答者基线T细胞克隆性高,提示治疗前外周血TCR克隆性可能预测持久应答。
要点
- 持续应答的ITP患者基线外周血T细胞克隆性较高
- ETB联合DEX组患者应答持续时间定性更长且补救药物使用定性减少
- 治疗前TCR克隆性可能作为ITP持久应答的预测指标
核心结论
- 治疗前外周血T细胞受体克隆性高与ITP患者持久应答相关。
研究设计与样本
- 基于XPAG-免疫性血小板减少症试验,包含DEX单药组和ETB联合DEX组。
主要发现
- 持续应答者基线T细胞克隆性高,而治疗无应答者不同。
- ETB联合DEX组患者应答持续时间定性更长,补救药物使用定性减少。
关键数值与推荐
- DEX组:地塞米松40 mg/天,第1-4天,每28天一个周期,1-3个周期,最长12周。
- ETB联合DEX组:艾曲泊帕起始50 mg/天用2周,未达血小板≥50×10^9/L者每2周增加25 mg;减量每2周减25 mg至最低25 mg隔日一次。
临床怎么用
- 治疗前检测外周血TCR克隆性可能有助于识别ITP持久应答患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Left panel: Scheme of the XPAG-immune thrombocytopenia trial. The dexamethasone (DEX) arm consisted of DEX 40 mg/day for days 1-4 for one to three cycles every 28 days to a maximum of 12 weeks, cycles 2 + 3 were optional. Patients randomised to eltrombopag (ETB) + DEX received eltrombopag in combination with a short course of high-dose DEX beginning on day 1 (40 mg/day during days 1-4). The starting dose of ETB was 50 mg/day for 2 weeks; thereafter, the ETB dose was increased by 25 mg for all patients who did not achieve the target platelet count of ≥50 × 109/L. The ETB tapering was performed by decreasing the dose by 25 mg every 2 weeks to a minimum dose of 25 mg every other day for all patients. Right upper panel: Clinical outcomes in patients treated with first-line ETB + DEX. Patients displayed a qualitatively longer response duration and qualitatively reduced usage of rescue medication. Right lower panel: The immunological T-cell response was different in treatment responders and non-responders. Patients with sustained response (responders) displayed a high T-cell clonality at baseline. Clones are depicted as bubbles (right side).
引用
- Schmidt-Barbo P, Schultheiss C, Jauch AJ, et al. High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia. Br J Haematol. 2026. PMID: 41486630. doi:10.1111/bjh.70310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。